登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 4 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 4
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 研究中心复旦大学附属眼耳鼻喉科医院Eye & ENT Hospital of Fudan University上海医院页面
- 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
- 研究中心上海交通大学医学院附属新华医院Xinhua Hospital上海医院页面
- 研究中心浙江省肿瘤医院Zhejiang Cancer Hospital杭州医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT06314334,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Patients who meet the diagnostic criteria for NKTCL (WHO-2016) based on pathological examination.
入选标准第 1 条
Primary lesions located in the upper respiratory and digestive tract such as the nasal cavity, sinuses, nasopharynx, oropharynx, or oral cavity, with clinical staging of IE/IIE based on PET/CT and bone marrow examination according to the Lugano 2014 criteria.
入选标准第 2 条
Eastern Cooperative Oncology Group performance status (ECOG) score of 0-2.
入选标准第 6 条
Evaluated for lymphoma response according to the Lugano 2014 criteria, with at least one measurable lesion or lesion assessable by PET/CT.
入选标准第 3 条
Patients co-infected with HCV, HIV, or HBV with plasma HBV-DNA >10\^3/ml.
排除标准第 1 条
Pregnant and lactating women.
排除标准第 7 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:既往治疗;化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06314334,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Patients who meet the diagnostic criteria for NKTCL (WHO-2016) based on pathological examination. Primary lesions located in the upper respiratory and digestive tract such as the nasal cavity, sinuses, nasopharynx, oropharynx, or oral cavity, with clinical staging of IE/IIE based on PET/CT and bone marrow examination according to the Lugano 2014 criteria. Evaluated for lymphoma response according to the Lugano 2014 criteria, with at least one measurable lesion or lesion assessable by PET/CT. No prior treatment with chemotherapy, radiotherapy, immunotherapy, or biological therapy for lymphoma. Age between 18 and 75 years, both genders. Eastern Cooperative Oncology Group performance status (ECOG) score of 0-2. Must have adequate organ and bone marrow function, defined as follows: Willing to comply with the study protocol, follow-up plan, and laboratory and ancillary investigations.排除标准:Exclusion Criteria:
Patients co-infected with HCV, HIV, or HBV with plasma HBV-DNA >10\^3/ml. Patients with a history of pancreatitis. Patients with acute or systemic infections requiring intravenous antibiotic therapy. Patients with severe complications such as hemophagocytic syndrome, DIC, etc. Significant organ dysfunction: such as respiratory failure, chronic congestive heart failure with NYHA class ≥2, decompensated liver or renal dysfunction, uncontrolled hypertension and diabetes despite aggressive treatment, and cardiovascular thrombotic or hemorrhagic events in the past 6 months. Patients with a history of autoimmune diseases who are not suitable for treatment with immune checkpoint inhibitors. Pregnant and lactating women. Patients with psychiatric disorders. Known allergies to drugs in the chemotherapy regimen. Patients with concomitant other tumors requiring surgery or chemotherapy within the past 6 months. Currently using other experimental drugs.
引自 ClinicalTrials.gov, NCT06314334, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06314334,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。